Edward B. Garon, MD, MS

Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.

A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.

Expert oncologists discuss patients who may progress to the second line setting with KRAS G12C mutations.

A comprehensive review of hepatotoxicity in ongoing studies evaluating KRAS inhibitors in the frontline setting, highlighting adagrasib and sotorasib in the KRYSTAL-7 and CodeBreaK 100 studies, respectively.

Joshua K. Sabari, MD, and Edward B. Garon, MD, MS, discuss the role and potential impact of KRAS G12C inhibitors in the frontline setting, highlighting the potential of monotherapy and in combination with a PD-1/PD-L1 inhibitor.

Shared insight into the consideration of KRAS G12C inhibitors in treating co-mutations in NSCLC.

Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.

Joshua K. Sabari, MD, reviews data from the TROPION-Lung04 study, and the panel offers key takeaways on Dato-DXd and immunotherapy in advanced NSCLC.

Experts review the current frontline treatments for patients with KRAS G12C-mutated NSCLC.

Explore the current landscape of targeted therapies in non-small cell lung cancer, focusing on KRAS G12C mutations, molecular testing, and current treatments.

Edward B. Garon, MD, MS, reviews data from the EVOKE-02 study, and the panel offers their thoughts on antibody-drug conjugates for the treatment of advanced NSCLC.

The expert panel reviews the results from the TROPION-Lung01 study and discusses how the data can inform treatment decisions for patients with previously treated NSCLC.

Solange Peters, MD, PhD, reviews key data from TROPION-Lung01 investigating datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non–small cell lung cancer.

Clinical insights on how the level of PD-L1 expression informs treatment decisions for patients with non–small cell lung cancer.

Experts on non–small cell lung cancer discuss the role of CTLA-4 inhibitors in the NSCLC treatment landscape.

A panel of thoracic medical oncologists provide an overview of first-line treatment strategies for advanced non–small cell lung cancer (NSCLC).

Edward B. Garon, MD, discusses the potential impact of the ongoing, phase 3 TROPION-LUNG01 trial in non–small cell lung cancer.

Edward B. Garon, MD, discusses immunotherapy treatment considerations for patients with non–small cell lung cancer.

Edward B. Garon, MD, MS, discusses the KEYNOTE-001 study, which examined the 5-year long-term overall survival in patients with non–small cell lung cancer treated with pembrolizumab.

The role of immunotherapy is emerging as an effective, and in some cases, dramatic treatment in the non-small cell lung cancer landscape.